DE:H5O0 Stock Latest News
Company AnnouncementsArgent BioPharma Reports All Ten AGM Resolutions Passed1d ago
Company AnnouncementsArgent BioPharma Licenses Non-Core Cannabis Genetics in Global Deal with Thai Phytomed3w ago
Company AnnouncementsArgent Biopharma sharpens immune focus and monetises CannEpil with new licensing deals4w ago
Company AnnouncementsArgent BioPharma Sets November Date for Annual General Meeting1M ago
Company AnnouncementsArgent BioPharma Sets AGM Date and Director Nomination Deadline1M ago
Company AnnouncementsArgent BioPharma Refines Immune Modulation Strategy Around Inflammation and Healthy Ageing1M ago
Company AnnouncementsArgent Biopharma Cancels Over 5.5 Million Convertible Notes2M ago
Company AnnouncementsArgent BioPharma Narrows Annual Loss After Restructuring and Cost Controls2M ago
Company AnnouncementsArgent Biopharma Details Governance Compliance in ASX Filing2M ago
Company AnnouncementsArgent BioPharma Secures FDA-CVM INAD for CannEpil Veterinary Cancer-Pain Program2M ago
Company AnnouncementsArgent Biopharma Plans Options and Convertible Notes Issue to Bolster Funding3M agoCompany AnnouncementsArgent BioPharma Advances CannEpil into U.S. Veterinary Market with New Development Program3M ago
Company AnnouncementsArgent Biopharma Options Expire Unexercised, Simplifying Capital Structure3M ago
Company AnnouncementsArgent BioPharma Extends CannEpil Licence into Global Veterinary Market3M ago
Company AnnouncementsArgent Biopharma Cuts Debt with CannEpil Deal and Expands Veterinary Pipeline3M ago
Company AnnouncementsArgent BioPharma Secures Additional Convertible Note Funding and Updates Capital Structure4M ago
Company AnnouncementsArgent Biopharma Issues 385,000 New Convertible Notes on ASX4M ago
Company AnnouncementsArgent Biopharma Plans New Unlisted Options Issue on ASX4M ago
